Quick Answer
AN2 Therapeutics, Inc. reported Net Income of -$35.17 million for fiscal year 2025.
AN2 Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$35.17M | +31.5% |
| 2024 | -$51.32M | +20.7% |
| 2023 | -$64.73M | -58.1% |
| 2022 | -$40.96M | -90.1% |
| 2021 | -$21.54M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.35M | +26.6% | -44.7% |
| June 30, 2025 | -$6.46M | +55.2% | +39.3% |
| March 31, 2025 | -$10.65M | +35.9% | +16.5% |
| September 30, 2024 | -$12.75M | +23.7% | +11.7% |
| June 30, 2024 | -$14.44M | +8.7% | +13.1% |
| March 31, 2024 | -$16.62M | -8.4% | +0.5% |
| September 30, 2023 | -$16.71M | -47.3% | -5.7% |
| June 30, 2023 | -$15.80M | -56.2% | -3.1% |
- AN2 Therapeutics, Inc. showed an increase of +31.5% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, AN2 Therapeutics, Inc.’s net income has declined by 63.3% (from -$21.54 million to -$35.17 million).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: